Date: Dec 15, 2011 Source: (
click here to go to the source)
Emerging biopharmaceutical achieves 858% sales growth over past three years
OKLAHOMA CITY, Aug. 19 /PRNewswire/ — Charlesson LLC, a specialty biopharmaceutical company, has been ranked by Inc. magazine as No. 264 on the 28th annual Inc. 500, an exclusive ranking of the fastest-growing private companies nationwide. Charlesson was also identified as the 23rd fastest-growing private company in the health category.
Charlesson was recognized as a result of its high growth rate, which totaled 858 percent over the past three years. Founded in 2003, Charlesson's primary focus is the development of treatments for eye diseases, including diabetic retinopathy, age-related macular degeneration and glaucoma. The company's expertise in ophthalmic drug development and delivery has also enabled it to establish a profitable contract research organization, which provides specialty preclinical ophthalmic services to major pharmaceutical companies.
"We are honored to be included in the prestigious group of companies in the Inc. 500 listing," said Mike Moradi, Chief Executive Officer of Charlesson. "Our ranking is a testament to the uniqueness of our ideas and the quality of our employees at Charlesson."
